Purpose Of Review: Relapsed or metastatic head and neck squamous cell carcinoma (R/M HNSCC) is a deadly disease that historically was treated with palliative chemotherapy-based regimens. Since 2019, immunotherapy-based regimens have become the standard of care for 1st line treatment in this disease. Over the last several years, there have been numerous studies conducted with novel combination therapies for R/M HNSCC but there has not yet been a new standard of care.
Recent Findings: Novel treatment combinations with chemotherapy, targeted therapy, immunotherapy, vaccines, and intratumoral drugs have been evaluated in the treatment of R/M HNSCC. Favorable efficacy has been seen with many of these combinations, although some large studies have failed to improve upon the current standard.
Summary: Many promising combination regimens are being tested which could lead to a new standard of care in the treatment of R/M HNSCC in the coming years.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/CCO.0000000000001127 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Case Report: Complete response to four cycles of camrelizumab in a PD-L1 negative patient with advanced oral squamous cancer.
Front Immunol
March 2025
Department of Otorhinolaryngology Head and Neck Surgery, The First Affiliated Hospital of Naval Medical University (Changhai Hospital of Shanghai), Shanghai, China.
Immunotherapy has brought better survival benefits in the treatment of recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). However, owing to the lack of relevant biomarkers that could predict the efficacy of this treatment, it often has to be maintained. Here we report on a patient with stage IVA squamous cell carcinoma of the tongue who developed an unresectable lesion in the neck after surgery and radical chemoradiotherapy.
View Article and Find Full Text PDFNovel immunotherapy combinations in head and neck squamous cell carcinoma.
Curr Opin Oncol
February 2025
University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California, USA.
Purpose Of Review: Relapsed or metastatic head and neck squamous cell carcinoma (R/M HNSCC) is a deadly disease that historically was treated with palliative chemotherapy-based regimens. Since 2019, immunotherapy-based regimens have become the standard of care for 1st line treatment in this disease. Over the last several years, there have been numerous studies conducted with novel combination therapies for R/M HNSCC but there has not yet been a new standard of care.
View Article and Find Full Text PDFClinical significance of peripheral T-cell repertoire in head and neck squamous cell carcinoma treated with cetuximab and nivolumab.
Cancer Immunol Immunother
March 2025
Department of Head and Neck-Endocrine Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 33612, USA.
Immunotherapy holds significant promise for treating head and neck squamous cell carcinoma (HNSCC), yet responses are limited to a subset of patients. This research investigates whether analyzing the peripheral T-cell receptor (TCR) repertoire could help identify patients who are more likely to benefit from a combination treatment of cetuximab and nivolumab. We report here updated correlative analysis using all samples profiled with deep immunoSEQ assay to study the peripheral TCR repertoires in peripheral blood mononuclear cells from patients enrolled in a phase I/II trial (NCT03370276).
View Article and Find Full Text PDFCurrent Progress and Future Directions of Immunotherapy in Head and Neck Squamous Cell Carcinoma: A Narrative Review.
JAMA Otolaryngol Head Neck Surg
March 2025
Department of Otolaryngology-Head and Neck Surgery, Harvard Medical School, Boston, Massachusetts.
Importance: For decades, the 3 therapeutic pillars for head and neck squamous cell carcinoma (HNSCC) have been radiation therapy, chemotherapy, and surgery. In recent years, a fourth pillar, immunotherapy, has shifted the existing paradigm of oncologic care by improving survival outcomes. This narrative review highlights key completed and ongoing clinical trials that have led to new therapeutic approaches and are aiming to further alter the current standard of care.
View Article and Find Full Text PDFCombined Tumor Infiltrating Lymphocytes and PD-L1 Status in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
Head Neck
March 2025
Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, Michigan, USA.
Objectives: To determine if the assessment of CD8+ tumor-infiltrating lymphocytes (TILs) adds prognostic information to the PD-L1 combined positive score (CPS) in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
Methods: A retrospective case series was performed of 77 patients with R/M HNSCC between 2003 and 2019. From pre-treatment biopsies, CD8+ TILs and PD-L1 CPS were quantified on a tissue microarray.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!